Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

US drug firm loses license after ignoring suspiciously large painkiller orders during opioid crisis

Morris & Dickson Co.'s license has been revoked by the US Drug Enforcement Administration (DEA) following a 68-page order by DEA Administrator Anne Milgram on the opioid crisis

Daily Mirror

DEA moves to revoke major drug distributor's license over opioid crisis failures

The agency says it will strip Morris & Dickson of its license to sell highly addictive painkillers after finding it failed to flag thousands of suspicious orders at the height of the opioid crisis.

WEKU

After yearslong delay, DEA revokes license of wholesale drug distributor over opioid crisis failures

The U.S. Drug Enforcement Administration has stripped one of the nation’s largest pharmaceutical distributors of its license to sell highly addictive painkillers after determining it failed to flag thousands of suspicious, high-volume orders at the height of the opioid crisis

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

US banker paid £73m dividend in 2021 after firm won millions in UK Covid contracts

Banks Bourne, sole owner of Tanner Pharma in North Carolina, took sum from Tanner’s UK arm, records show

The Guardian - UK

Analysts expect Medtronic to deliver frank financial answers this week

Medtronic is facing sluggish sales growth, is in the midst of deep cost-cutting and started ongoing global layoffs in April. It's also spinning off businesses with weaker profit margins.

Tribune News Service

3 Biotech Stocks Losing Market Value

There is a growing demand for healthcare solutions, and the biotech industry will likely benefit from it. However, not all biotech stocks are well-positioned to capitalize on the industry tailwinds. Therefore, investors could look to avoid fundamentally weak biotech stocks Bicycle Therapeutics (BCYC), CorMedix (CRMD), and 22nd Century Group (XXII).…

StockNews.com

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

GOP moves to limit abortion pill in US

A House panel advanced a 2024 budget bill that would block the ability to access the abortion drug via telehealth

Salon

Takeaways of AP report on DEA probe of drug distributor accused of fueling opioid epidemic

The U.S. Drug Enforcement Administration has allowed one of the nation’s largest drug distributors to keep shipping addictive painkillers for nearly four years despite a judge’s recommendation to strip its license for turning a blind eye to thousands of suspicious opioid orders

The Independent UK

Invest in These 3 Biotech Stocks Today

With the biotech industry experiencing significant growth due to the increasing demand for healthcare solutions, fundamentally sound stocks such as Amicus Therapeutics (FOLD), POINT Biopharma Global (PNT), and Precision BioSciences (DTIL) might have the potential to provide substantial returns for investors and could be valuable portfolio additions this month. Learn…

StockNews.com

Johnson & Johnson (JNJ) and SNDL Inc. (SNDL) -- Buy or Sell?

Investing in healthcare stocks could help hedge against economic downturns. Thus, Johnson & Johnson (JNJ) could be worth buying. However, I think SNDL (SNDL) is best avoided considering its weak fundamentals. Read on.

StockNews.com

Explained | What is the National Medical Devices Policy, 2023?

On April 26, the Union Cabinet approved the National Medical Devices Policy, 2023.Here are the various reasons why it is imporetant

The Hindu

HRT medicine Utrogestan restricted in UK amid shortages

Pharmacists can only dispense maximum of two months’ supply for every prescription as supplier struggles to meet demand

The Guardian - UK

2 Explosive Biotech Stocks to Own

The biotech industry is well-positioned to grow, thanks to breakthrough advances, rising chronic illness and government support. So, fundamentally solid biotech stocks, Genmab (GMAB) and Exelixis (EXEL) may be worth buying now. Read on.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Dr. Reddy's Laboratories (RDY) Is the Pharmaceutical Stock to Buy

Dr. Reddy's Laboratories (RDY) delivered exceptional performance, as its fourth-quarter profits grew by an astonishing eleven-fold. By deftly expanding its product line-up and fortifying its market presence, the company sets the stage for significant growth, which could establish it as the go-to pharmaceutical stock to invest in. Read more….

Bangkok Post

AstraZeneca China boss pledges to ‘love the Communist Party’

BEIJING: The global drugmaker AstraZeneca will seek to be a patriotic company in China that “loves the Communist Party”, its China president said on Friday.

StockNews.com

2 Pharma Stocks Investors Are Flocking

The pharmaceutical industry is expected to thrive amid robust demand and government support. Given the solid long-term prospects of the industry, investors should consider buying pharma stocks Ironwood Pharmaceuticals (IRWD) and Calliditas Therapeutics (CALT). Read on.

StockNews.com

2 Pharma Stocks to Watch Like a Hawk

From innovative drug pipelines to innovative research, the pharma sector offers a vast array of investment opportunities. Thus it would be wise to keep an eye on quality stocks Ipsen S.A.(IPSEY) and Kamada (KMDA), which hold considerable potential. Read more….

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

How mifepristone became a target of the US anti-abortion movement

The abortion pill, first invented in 1980 in France, was slow to be accepted in the US. Now, it’s at the center of a major court fight

The Guardian - AU

Australian pharmacy losses predicted to total $1.2bn over four years under Labor prescription reforms

Government models also outline benefits to patients as guild says changes will send small and regional businesses ‘to the wall’

StockNews.com

3 Buy Worthy Biotech Stocks for May

The biotech industry is well-positioned to witness significant growth with government support and breakthrough developments. Therefore, biotech stocks BioNTech SE (BNTX), Acorda Therapeutics (ACOR), and Shionogi (SGIOY) might be solid buys. Read on.

StockNews.com

3 Biotech Stocks Poised to Skyrocket

On the backs of successful trials and breakthrough therapies, the biotech market is poised to thrive. Therefore, scooping up the shares of fundamentally sound biotech stocks such as BioMarin Pharmaceutical (BMRN), Incyte Corp. (INCY), and Innoviva (INVA) could be beneficial. Read more….

Birmingham Post

University of Bristol spin-out secures £415,000 for disease detection tech

Rosa Biotech said it would use the money to accelerate testing of its platform, which acts as a biosensor on patient blood samples

Daily Mirror

Healthcare firm owned by Tory grandee landed £53million in NHS contracts

Tory grandee Lord Ashcroft controlled Medacs Healthcare when it was handed 10 NHS deals worth up to £53million between September 2021 and December 2022, contract notices have revealed

StockNews.com

Best Medical Stock Investors Should Buy in a Recession

Despite the cooling down of inflation, a Fed rate cut is not in sight. Amid recessionary concerns, investing in medical stock Abbott Laboratories (ABT) could be wise given its sound financials and the inherent stability of the medical sector. Let’s take a look at some of the company’s key metrics….

1 … 52 53 54 55

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University of Bristol

207 stories

The Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.